Wegovy denied? Read the reason before you accept it.
Wegovy (semaglutide) denials usually cite step therapy, a weight-loss exclusion, or missing prior-authorization documentation — and each of those has a different, specific answer. Out of pocket, Wegovy often runs well over $1,000 a month, so the appeal is usually worth writing.
Upload your denial letter. Lysco identifies the exact reason, maps the arguments that fit it — including Wegovy’s cardiovascular indication where your records support it — and drafts the appeal. Your first read is free.
Free to see exactly what’s wrong. $9 to unlock the full appeal — only if you choose to proceed. No subscription.
The Wegovy-specific lever
The cardiovascular indication can reframe a “weight loss” denial
In March 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight (based on the SELECT trial).
That matters for appeals: many plans exclude “weight-management” indications while covering cardiovascular treatment. If your medical record documents established cardiovascular disease — for example a prior heart attack, stroke, or peripheral arterial disease — and you meet the label criteria, the request can be framed as cardiovascular risk reduction, not cosmetic weight loss.
What the appeal needs: documentation of the qualifying cardiovascular diagnosis, your BMI history, and a prescriber statement tying the prescription to the FDA-labeled cardiovascular indication. Whether the indication applies to you is a clinical question for your prescriber — Lysco is informational only and never prescribes.
Denial playbook
The four Wegovy denials — and what answers each
Step therapy: “try a cheaper drug first”
Plans commonly require documented trials of older options (for example phentermine or Saxenda) before Wegovy. If you already tried and failed one, could not tolerate it, or it is contraindicated for you, that is a recognized exception — the appeal documents it. See the step-therapy guide for the full exception grounds and state override laws.
Weight-loss indications excluded by the plan
A plan-design exclusion is the hardest denial type — but the cardiovascular indication above, a covered comorbidity, or a formulary-exception request can still change the outcome. The free first read tells you honestly whether your documents support one of those paths.
Prior-authorization criteria “not met”
FDA labeling for Wegovy covers adults with BMI ≥30, or ≥27 with at least one weight-related condition — common FDA-labeled adult indications, not a universal plan coverage standard. Plans layer their own criteria on top; the appeal compares what the denial cited against the plan’s actual written policy and your chart.
Formulary position: a different GLP-1 is preferred
If the plan prefers another GLP-1, a formulary-exception request with clinical justification for why your prescriber chose Wegovy is the standard route. Under 45 CFR 156.122, marketplace and other essential-health-benefit plans must decide standard formulary-exception requests within 72 hours (24 hours if expedited).
Worth knowing
Two Wegovy facts that shape appeals in 2026
Wegovy and Ozempic are the same molecule, different labels. Both are semaglutide, but Ozempic is FDA-labeled for Type 2 diabetes and Wegovy for weight management and cardiovascular risk reduction. Plans treat them as different products — an indication mismatch between what was prescribed and what the plan covers is a common, sometimes correctable, denial driver.
On CVS Caremark’s main commercial formulary, Wegovy became the preferred obesity GLP-1 in July 2025. If Caremark manages your benefit, a Wegovy denial is usually about prior-authorization criteria or a plan exclusion rather than formulary position — which changes what the appeal argues. Switched off Zepbound? See that guide.
Build the record
What a strong Wegovy appeal attaches
The denial letter itself — the exact cited reason drives the whole appeal
BMI history and any weight-related conditions from your chart (hypertension, high cholesterol, sleep apnea, prediabetes)
Records of prior weight-management treatments tried and their outcomes — the step-therapy answer
For the cardiovascular path: documentation of established cardiovascular disease and a prescriber statement tying Wegovy to the FDA-labeled indication
Your plan’s own written coverage policy for Wegovy — you can request it in writing, and the appeal quotes it back
Honest odds: in 2024 ACA Marketplace data (KFF), fewer than 1% of denied in-network claims were formally appealed — and of the appeals that were filed, about 1 in 3 ended with the denial overturned internally. Those are population numbers, not a prediction for your case; outcomes depend on your plan, denial reason, and documentation. Nobody can promise your appeal will win — anyone who does is selling something.
Questions
Wegovy denial questions, answered straight
Why did my insurance deny Wegovy?
The most common reasons are step therapy (the plan wants you to try a cheaper drug first), a plan-design exclusion of weight-management drugs, prior authorization criteria the paperwork didn’t document, or a formulary position that prefers a different GLP-1. Each has a different appeal path — the denial letter’s exact wording tells you which one you’re facing.
Does Wegovy’s heart-health approval change my appeal?
It can. In March 2024 the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight. If your medical record documents established cardiovascular disease and you meet the label criteria, the claim can be framed as cardiovascular risk reduction rather than weight loss — which matters when the plan excludes “weight-loss” indications. Whether it applies depends on your documented diagnosis; this is informational, not medical advice.
My plan covers Ozempic but denied Wegovy. Aren’t they the same drug?
Both contain semaglutide, but they are separately FDA-labeled products — Ozempic for Type 2 diabetes, Wegovy for weight management and cardiovascular risk reduction. Plans price and cover them differently, and a diabetes-versus-weight indication mismatch is a common, sometimes correctable, driver of denials. An appeal or formulary-exception request can address it, but a plan is not required to treat the two as interchangeable.
How much does Lysco cost?
Your first read is free — upload the denial and see exactly what went wrong and your appeal options. If you proceed, it is a flat $9 to unlock the full ready-to-sign appeal and submission instructions. No subscription, no credit card to start.
Start your Wegovy appeal — free
Your first read is free. 30 seconds to upload. No credit card needed.
Appeal my Wegovy denialEncrypted in transit and at rest · Access controlled · Delete anytime
Lysco is an informational tool — not a law firm, medical provider, or licensed patient advocate. We don’t prescribe or recommend medications; whether any indication applies to you is a decision for you and your doctor. Appeal outcomes vary by plan, diagnosis, documentation, and circumstances. This page is not medical or legal advice. Wegovy and Ozempic are trademarks of Novo Nordisk A/S.